# ScoreItem: Doppler Aorta - PSV Art√©ria Renal

**ID:** `c77cedd3-2800-7068-927c-db125905c0d3`
**FullName:** Doppler Aorta - PSV Art√©ria Renal (Exames - Imagem)
**Unit:** cm/s

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 17 artigos
- Avg Similarity: 0.507

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `c77cedd3-2800-7068-927c-db125905c0d3`.**

```json
{
  "score_item_id": "c77cedd3-2800-7068-927c-db125905c0d3",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Doppler Aorta - PSV Art√©ria Renal (Exames - Imagem)
**Unidade:** cm/s

**30 chunks de 17 artigos (avg similarity: 0.507)**

### Chunk 1/30
**Article:** Critical analysis of renal duplex ultrasound parameters in detecting significant renal artery stenosis (2012)
**Journal:** Journal of Vascular Surgery
**Section:** abstract | **Similarity:** 0.704

Large study of 313 patients evaluating Doppler parameters for renal artery stenosis. Mean renal-aortic ratios for normal, <60%, and ‚â•60% stenosis were 2.2, 2.9, and 4.5 respectively. RAR >3.5 demonstrated high diagnostic accuracy for detecting hemodynamically significant stenosis.

---

### Chunk 2/30
**Article:** Doppler ultrasound and renal artery stenosis: An overview (2013)
**Journal:** Journal of Ultrasound
**Section:** abstract | **Similarity:** 0.695

Overview of Doppler ultrasound techniques for diagnosing renal artery stenosis, the most common cause of secondary hypertension. Discusses renal-aortic ratio as a reliable parameter that normalizes individual hemodynamic variations, improving diagnostic specificity compared to peak systolic velocity alone.

---

### Chunk 3/30
**Article:** Doppler Renal Assessment, Protocols, and Interpretation (2024)
**Journal:** StatPearls
**Section:** abstract | **Similarity:** 0.672

Comprehensive review of renal Doppler ultrasound techniques, including renal-aortic ratio (RAR) for detecting renal artery stenosis. The RAR compares intrastenotic flow velocity in renal arteries with aortic reference values, with RAR >3.5 predicting ‚â•60% stenosis with 84-91% sensitivity and 95-97% specificity.

---

### Chunk 4/30
**Article:** Optimal Peak Systolic Velocity Thresholds for Predicting Internal Carotid Artery Stenosis Greater than or Equal to 50%, 60%, 70%, and 80% (2016)
**Journal:** Journal of Stroke and Cerebrovascular Diseases
**Section:** abstract | **Similarity:** 0.567

The research established optimal peak systolic velocity measurements for detecting various degrees of internal carotid artery stenosis. Testing 127 arterial specimens, researchers identified specific thresholds: 130 cm/s, 160 cm/s, 200 cm/s, and 270 cm/s for detecting stenosis at increasing severity levels (‚â•50%, ‚â•60%, ‚â•70%, and ‚â•80% respectively). The findings demonstrated high diagnostic accuracies across all measured thresholds, with sensitivity and specificity values exceeding 85% for each threshold category.

---

### Chunk 5/30
**Article:** Correlation between Ultrasound Peak Systolic Velocity and Angiography for Grading Internal Carotid Artery Stenosis (2024)
**Journal:** Journal of Clinical Medicine
**Section:** abstract | **Similarity:** 0.541

The study evaluated how peak systolic velocity (PSV) measured via duplex ultrasound correlates with angiography findings for assessing internal carotid artery stenosis. Researchers analyzed 47 stenotic lesions using both ultrasound and digital subtraction angiography, applying NASCET and ECST classification protocols. Key findings indicated that a PSV threshold of 200 cm/s was found to be the best criterion for identifying severe NASCET stenoses (‚â•70%), while a threshold of 180 cm/s was the best for ECST stenoses (‚â•80%). However, PSV demonstrated limited reliability for moderate stenoses, suggesting complementary imaging techniques should be employed in such cases.

---

### Chunk 6/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.527

ardiovasculardiseaseandantithrombotictherapy.EurHeartJ.2013;34:1708‚Äì1713,1713a‚Äì1713b.697.JamesS,BudajA,AylwardP,etal.Ticagrelorversusclopidogrelinacutecoronarysyndromesinrelationtorenalfunction:resultsfromthePlateletInhibitionandPatientOutcomes(PLATO)trial.Circulation.2010;122:1056‚Äì1067.698.HerringtonWG,StaplinN.InpatientswithcoronarydiseaseandCKD,
addinganinvasivestrategytoMTdidnotimproveoutcomes.AnnInternMed.2020;173:JC16.699.SarnakMJ,AmannK,BangaloreS,etal.Chronickidneydiseaseand
coronaryarterydisease:JACCstate-of-the-artreview.JAmCollCardiol.2019;74:1823‚Äì1838.700.CharytanDM,WallentinL,LagerqvistB,etal.Earlyangiographyin
patientswithchronickidneydisease:acollaborativesystematicreview.ClinJAmSocNephrol.2009;4:1032‚Äì1043.701.HastingsRS,HochmanJS,DzavikV,etal.Effectoflaterevascularization
ofatotallyoccludedcoronaryarteryaftermyocardialinfarctiononmortalityratesinpatientswithrenalimpairment.AmJCardiol.2012;110:954‚Äì960.702.JohnstonN,JernbergT,LagerqvistB,etal.Earlyinvasivetrea

---

### Chunk 7/30
**Article:** Dislipdemia (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.527

quais ~250 mil ocorrem antes dos 60 anos.
- Brasil: 410 mil mortes/ano por DCV; 14 milh√µes com alguma DCV; 36% dos √≥bitos ‚â•55 anos decorrem de doen√ßa cardio-circulat√≥ria.
- Fisiopatologia: fluxo arterial torna-se turbilhonado ~50% de estenose, aumentando estresse de parede e risco de ruptura de placa.
**Achados Adicionais**
- LDL alvo em baixo risco: diretriz sugere <130 mg/dL (por vezes <100), mas o n√∫mero isolado n√£o determina benef√≠cio sem DCV pr√©via e sem avalia√ß√£o de part√≠culas/c√°lcio.
- LDL basal em estudo: 190 mg/dL; colesterol total 275 e HDL 31, ilustrando perfis iniciais elevados; em pacientes com c√°lcio zero, LDL >240 n√£o alterou mortalidade/infarto com estatina.

---

### Chunk 8/30
**Article:** Terapia de Reposi√ß√£o Hormonal com Testosterona XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.500

nsiderado alterado (normal > 15 ml/s).
- O tratamento medicamentoso para HPB inclui doses como 0,4 mg de Tansulosina ou 2 a 4 mg de Doxazosina para relaxar a musculatura e melhorar o fluxo urin√°rio.
### Achados Adicionais Chave
- A resson√¢ncia magn√©tica multiparam√©trica 3 Tesla √© uma ferramenta de alta defini√ß√£o, recomendada a partir dos 40 anos para homens com hist√≥rico familiar ou a partir dos 50 anos como rotina para uma avalia√ß√£o prost√°tica precisa.
- A dosagem hormonal salivar oferece uma medi√ß√£o precisa dos horm√¥nios livres, com faixas de refer√™ncia para testosterona (47-150), estradiol (0.6-3) e o quociente estrog√™nico (0.04-1.67), que avalia o equil√≠brio hormonal.
- A escala Gleason, que vai de 1 a 10, mede a agressividade do c√¢ncer de pr√≥stata, com tumores classificados como 8, 9 ou 10 sendo considerados os mais agressivos.
- A hiperplasia prost√°tica √© uma condi√ß√£o que afeta apenas 3 esp√©cies: humanos, c√£es e macacos.

---

### Chunk 9/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.496

nal (sistema renina-angiotensina-aldosterona - SRAA), renal, microbiota e endot√©lio.
    *   **Mecanismos de Controle:** R√°pidos (neurais), m√©dio prazo (hormonais, alvo principal dos f√°rmacos) e longo prazo (controle de volemia pelo rim).
*   **Diagn√≥stico e Classifica√ß√£o:**
    *   A medi√ß√£o em consult√≥rio √© criticada; recomenda-se MAPA (Monitoriza√ß√£o Ambulatorial) ou MRPA (Monitoriza√ß√£o Residencial) para um diagn√≥stico preciso.
    *   **Valores de Refer√™ncia para Diagn√≥stico:** ‚â• 140/90 mmHg (consult√≥rio), ‚â• 130/80 mmHg (MAPA 24h), ‚â• 135/85 mmHg (MRPA).
    *   **Classifica√ß√£o (a partir de 18 anos):**
        *   **√ìtima:** < 120/80 mmHg.
        *   **Normal:** 120-129 / 80-84 mmHg.
        *   **Pr√©-hipertens√£o:** 130-139 / 85-89 mmHg.
        *   **Hipertens√£o Est√°gio 1:** 140-159 / 90-99 mmHg.
        *   **Hipertens√£o Est√°gio 2:** 160-179 / 100-109 mmHg.
        *   **Hipertens√£o Est√°gio 3:** ‚â• 180/110 mmHg.
### 3.

---

### Chunk 10/30
**Article:** Peak systolic velocity ratio for evaluation of internal carotid artery stenosis correlated with plaque morphology: substudy results of the ANTIQUE study (2023)
**Journal:** Frontiers in Neurology
**Section:** abstract | **Similarity:** 0.494

This study evaluated how effectively four duplex sonography measurements assess carotid artery narrowing severity when compared against computed tomography angiography. The research examined 143 patients with significant stenosis, analyzing peak systolic velocity (PSV), velocity ratios, end-diastolic velocity, and B-mode imaging. Results demonstrated that the PSV ICA/CCA ratio showed the highest correlation with CTA, followed by PSV and other parameters. The study found that plaque composition significantly influenced measurement accuracy, with calcified plaques producing substantially weaker correlations than softer plaque types with smooth surfaces.

---

### Chunk 11/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.487

ustold,butvery
old,andincorporatesmoreandmorepeopleovertheageof80.Octo-andnonagenariansoftendemonstratedistinctpatternsofdiseasecomplexity.Thesefeaturesincludemulti-
morbidityoftenaccompaniedbypolypharmacy,frailty,
cognitiveimpairment,andgerontopsychiatricdisordersamongothers.Often,severalofthesefeaturescoexistespe-
ciallyinolderadultswithCKD.ImplicationsforagingadultswithCKDareimportantinbothdiagnosisandtreatment.Theinterpretationoflabora-toryresults(specicallySCr)usedinthestagingsystemshouldfactorinanolderadult‚Äôshabitusgiventhefrequencyofsarcopenia.Acreatinine-basedeGFR(eGFRcr)willover-estimateGFRintheelderly(andothers)withsarcopenia
leadingtodrugoverdosing.UrineACRatthesametimewill
befalselyhighduetothefalselylowcreatinineinthede-
nominator.Furthermore,thepresenceoffrailtymayalter
treatmenttargetsrecommendedforyoungerpeoplewithCKD,astheymaynotnecessarilybetransferabletoolderadults.StrictBP-lowering,forexample,maycomewiththe
riskofdizziness,falls,andfracturesinolderadults,manyof
w

---

### Chunk 12/30
**Article:** Urea levels and cardiovascular disease in patients with chronic kidney disease (2022)
**Journal:** Nephrology Dialysis Transplantation
**Section:** other | **Similarity:** 0.485

20.3(5.1)0%Ageatbaseline(years)69[61‚Äì77]68[60‚Äì76]69[61‚Äì77]69[61‚Äì77]0.130%Men,n(%)666566670.710Smoking,n(%)0.030.8Never-smoker,n(%)40.644.539.637.7Currentsmoker,n(%)12.611.711.814.4Formersmoker,n(%)46.843.848.547.9eGFRatbaseline(mL/min/1.73m)33.5(11.6)43.5(9.9)32.6(8.9)24.5(7.0)<0.0010%Albumin-orprotein-to-creatinineratio<0.0018.0A1(normaltomildlyincreased),n(%)28.642.127.016.9A2(moderatelyincreased),n(%)31.831.833.729.7A3(severelyincreased),n(%)39.626.139.253.4Bodymassindex(kg/m)28.8(5.8)28.3(5.2)28.7(5.9)29.5(6.3)<0.0012.0%Diabetes,n(%)44.836.843.953.6<0.0010.2Systolicbloodpressure(mmHg)142(20)142(20)142(21)143(20)0.322.3%Historyofcardiovasculardisease,n(%)53.947.354.659.6<0.0011.3Anaemia,n(%)38.321.135.857.8<0.0010.3Serumbicarbonate(mmol/L)25.0(3.4)25.8(3.1)24.9(3.3)24.1(3.6)<0.0016.9%Serumalbumin(g/L)40.4(4.5)40.6(4.4)40.5(4.2)39.9(4.9)0.00915.2%High-sensitivityC-reactiveprotein(mg/L)2.5[1.1‚Äì5.9]2.2[1.1‚Äì5.0]2.5[1.1‚Äì5.4]2.9[1.2‚Äì7.1]<0.00117.6%Historyofacutekidneyinj

---

### Chunk 13/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.484

 10460‚Äì8945‚Äì5930‚Äì44<30105+90‚Äì104
60‚Äì8945‚Äì5930‚Äì44<30105+90‚Äì10460‚Äì8945‚Äì5930‚Äì44<30105+90‚Äì10460‚Äì89
45‚Äì59Urine albumin-creatinine ratio, mg/gUrine albumin-creatinine ratio, mg/gAll-cause mortality: 11 cohorts692 802 participants; 97 006 eventsMyocardial infarction: 10 cohorts649 365 participants; 17 926 eventsKidney failure with replacement therapy: 5 cohorts 630 370 participants; 4306 eventsHeart failure: 9 cohorts641 298 participants; 27 406 eventsCardiovascular mortality: 11 cohorts692 322 participants, 25 322 eventsStroke: 9 cohorts662 605 participants; 16 909 eventsAcute kidney injury: 5 cohorts630 370 participants; 24 062 events
607 102 participants; 37 278 eventsHospitalization: 3 cohorts630 489 participants; 464 894 eventsPeripheral artery disease: 6 cohorts642 624 participants; 3943 events30‚Äì44<30300+1.01.31.62.50.91.21.42.8ref1.31.52.0ref1.21.41.81.21.51.92.51.21.41.51.91.72.22.53.31.61.92.33.3
2.32.63.44.42.12.63.13.33.64.05.57.15.13.04.95.01.01.41.8

---

### Chunk 14/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.481

# Hipertens√£o Arterial Sist√™mica

**Source:** https://web.plaud.ai/share/1dd61764908881487::YXdzOnVzLXdlc3QtMg

---

## Lecture

Data e Hora: 2025-11-20 20:43:21
Local: [Inserir Local]
Instrutor: Tullius Pervi (T√∫lio)
## üìù Resumo
A aula, ministrada pelo Dr. Tullius Pervi (T√∫lio), cardiologista, oferece uma vis√£o abrangente sobre a hipertens√£o arterial sist√™mica, abordando-a como uma doen√ßa cr√¥nica, multifatorial e frequentemente assintom√°tica, que constitui um grave problema de sa√∫de p√∫blica. A apresenta√ß√£o detalha a defini√ß√£o, diagn√≥stico, preval√™ncia e fatores de risco, como idade, obesidade e gen√©tica. √â destacada a import√¢ncia de um diagn√≥stico preciso, diferenciando a hipertens√£o prim√°ria da secund√°ria e criticando a falta de rastreio para causas como apneia do sono. A fisiopatologia complexa √© explicada, envolvendo m√∫ltiplos sistemas.

---

### Chunk 15/30
**Article:** Comparing Carotid Artery Velocities with Current ASCVD Risk Stratification: A Novel Approach to Simpler Risk Assessment (2024)
**Journal:** Journal of Epidemiology and Global Health
**Section:** abstract | **Similarity:** 0.481

This prospective study examined 1,636 participants aged 40‚Äì75 years without prior cardiovascular events to explore whether carotid artery blood flow measurements could simplify ASCVD risk assessment. Researchers used duplex ultrasonography to measure flow velocities and compared results against standard 2022 USPSTF risk guidelines. The investigation revealed that end diastolic velocity (EDV) of common carotid artery (CCA) and the peak systolic velocity (PSV) of internal carotid artery (ICA) were inversely and nonlinearly associated with cardiovascular event risk. Optimal cutoff velocities were identified: approximately 23.75 cm/s for CCA-EDV, 81.75 cm/s for ICA-PSV, and 26.75 cm/s for ICA-EDV. Analysis showed U-shaped relationships suggesting these measurements could complement existing risk assessment methods for primary cardiovascular prevention.

---

### Chunk 16/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.481

m DCV), condi√ß√µes gestacionais (pr√©-termo, hipertensivas, diabetes gestacional), autoimunidade, tratamento de c√¢ncer de mama e defici√™ncias hormonais (climat√©rio/menopausa), frequentemente subvalorizadas nos protocolos. O palestrante defende abordagem multidisciplinar e estruturada de estilo de vida, especialmente em hipertens√£o lim√≠trofe, apoiada por nutricionistas e educa√ß√£o para ades√£o.
O uso de estatinas √© discutido criticamente: reconhece-se benef√≠cio anti-inflamat√≥rio local no p√≥s-angioplastia (les√£o de parede e fragilidade do stent), por√©m questiona-se o uso indiscriminado, sobretudo em preven√ß√£o prim√°ria, citando meta-an√°lise que desafia a hip√≥tese lip√≠dica e alertando para vieses na interpreta√ß√£o de risco relativo vs. absoluto. Em UTI, menciona-se aumento de del√≠rio e a necessidade de evitar ‚Äúreceita de bolo‚Äù (anticoagula√ß√£o, IBP, estatina autom√°tica).

---

### Chunk 17/30
**Article:** Dislipidemias II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.479

dade, inatividade f√≠sica, press√£o arterial e dislipidemia.
- A inflama√ß√£o √© indicada por marcadores como a Prote√≠na C-Reativa (PCR), onde um valor de 5 j√° √© considerado elevado, e a Interleucina 6 (exemplo de paciente com 8.45).
- A resposta anti-inflamat√≥ria √© medida pela Interleucina 10, com um valor de corte de 3,5 (abaixo disso √© um risco) e um exemplo de paciente com 6.44.
- A sa√∫de do endot√©lio √© avaliada pelo √≥xido n√≠trico, que deve estar em 8.8; um paciente com 4.8 j√° apresenta disfun√ß√£o sist√™mica.
- A LDL oxidada √© um marcador cr√≠tico, com um limite saud√°vel de 133, enquanto pacientes de alto risco podem apresentar valores extremos, como 1000.
**Achados Adicionais**
- Existem cinco par√¢metros cl√°ssicos para definir a s√≠ndrome metab√≥lica.
- O alvo de LDL para pacientes de alto risco, segundo as diretrizes atuais, √© de 50.

---

### Chunk 18/30
**Article:** Terapia de Reposi√ß√£o Hormonal com Testosterona XII (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.479

saltos abruptos (ex: de 2.5 para 4 ou 5 em dois meses) exigem investiga√ß√£o, mesmo dentro da faixa de normalidade.
**O diagn√≥stico e manejo da Hiperplasia Prost√°tica Benigna (HPB) dependem mais dos sintomas obstrutivos, como res√≠duo p√≥s-miccional acima de 40 ml, do que do tamanho da pr√≥stata, que pode variar de 25 a mais de 80 gramas sem necessariamente causar problemas.**
- A HPB √© comum a partir dos 45-50 anos, mas o tamanho da pr√≥stata (normalmente 25-30 gramas) n√£o se correlaciona diretamente com a obstru√ß√£o; pr√≥statas de 28-29 gramas podem ser obstrutivas, enquanto outras de 70-80 gramas n√£o.
- Um indicador chave de obstru√ß√£o √© o res√≠duo p√≥s-miccional, com volumes acima de 40 ml sendo anormais, e a urofluxometria, onde um fluxo m√°ximo (Qmax) abaixo de 10 ml/s √© considerado alterado (normal > 15 ml/s).
- O tratamento medicamentoso para HPB inclui doses como 0,4 mg de Tansulosina ou 2 a 4 mg de Doxazosina para relaxar a musculatura e melhorar o fluxo urin√°rio.

---

### Chunk 19/30
**Article:** The role of red blood cell distribution width (RDW) in cardiovascular risk assessment: useful or hype? (2019)
**Journal:** Annals of Translational Medicine
**Section:** abstract | **Similarity:** 0.474

Red cell distribution width (RDW) has emerged as a prognostic marker across multiple cardiovascular conditions. Reference range 12-15%. Each 1% increase in RDW associates with 1.10-fold higher all-cause mortality risk in heart failure. RDW >15% shows 3-fold increased mortality in CAD, 37% higher stroke risk, and 77% higher atrial fibrillation incidence.

---

### Chunk 20/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.472

actory to treatment‚â•4 antihypertensive agents‚Ä¢ Persistent abnormalities of serum potassium‚Ä¢ Acidosis‚Ä¢ Anemia‚Ä¢ Bone disease‚Ä¢ Malnutrition
Figure48|Circumstancesforreferraltospecialistkidneycareservicesandgoalsofthereferral.ACR,albumin-to-creatinineratio;AER,albuminexcretionrate;CKD,chronickidneydisease;eGFR,estimatedglomerularltrationrate;KRT,kidneyreplacementtherapy;PCR,protein-creatinineratio;PER,proteinexcretionrate;RBC,redbloodcells.

---

### Chunk 21/30
**Article:** Confounders in Identification and Analysis of Inflammatory Biomarkers in Cardiovascular Diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.472

atherosclerosis:Resultsfromaprospective,parallel-groupcohortstudy.Clin.Chim.Acta2015,447,16‚Äì22.[CrossRef]101.Hijazi,Z.;Lindahl,B.;Oldgren,J.;Andersson,U.;Lindb√§ck,J.;Granger,C.B.;Alexander,J.H.;Gersh,B.J.;Hanna,M.;Harjola,V.;etal.RepeatedMeasurementsofCardiacBiomarkersinAtrialFibrillationandValidationoftheABCStrokeScoreOverTime.J.Am.HeartAssoc.2017,6,e004851.[CrossRef]102.Abramson,J.L.;Lewis,C.;Murrah,N.V.;Anderson,G.T.;Vaccarino,V.RelationofC-ReactiveProteinandTumorNecrosisFactor-AlphatoAmbulatoryBloodPressureVariabilityinHealthyAdults.Am.J.Cardiol.2006,98,649‚Äì652.[CrossRef]103.Simundic,A.-M.;Kackov,S.;Miler,M.;Fraser,C.G.;Petersen,P.H.TermsandSymbolsUsedinStudiesonBiologicalVariation:TheNeedforHarmonization.Clin.Chem.2015,61,438‚Äì439.[CrossRef]
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

Biomolecules2021,11,1464
17of17
104.Khuseyinova,N.;Greven,S.;R√ºckerl,R.;Trischler,G.;Loewel,H.;Peters,A.;

---

### Chunk 22/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.471

‚Äì891.01.11.31.51.81.01.31.845‚Äì591.31.31.51.72.11.51.72.1Urine albumin-creatinine rg/gm ,oitar eninitaerc-nimubla enirUg/gm ,oitaAll-cause mortality: 82 cohorts26 444 384 participants; 2 604 028 events Myocardial infarction: 64 cohorts 22 838 356 participants; 451 063 events Kidney failure with replacement therapy: 57 cohorts 25 466 956 participants; 158 846 events Heart failure: 61 cohorts24 603 016 participants; 1 132 443 events Cardiovascular mortality: 76 cohorts26 022 346 participants; 776 441 events Stroke: 68 cohorts24 746 436 participants; 461 785 events Acute kidney injury: 49 cohorts23 914 614 participants; 1 408 929 events 
22 886 642 participants; 1 068 701 events Hospitalization: 49 cohorts25 426 722 participants; 8 398 637 events Peripheral artery disease: 54 cohorts24 830 794 participants; 378 924 events 30‚Äì441.51.51.61.92.32.01.92.515‚Äì291.81.81.92.42.83.33.33.8<152.72.83.03.23.89.19.09.6300‚Äì9991000+2.73.82.23.22.23.12.83.73.24.34.25.16.06.03.14.32.43.12.23.02.3

---

### Chunk 23/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.468

.Diagnosticaccuracyofpoint-of-caretestsfordetectingalbuminuria:a
systematicreviewandmeta-analysis.AnnIntMed.2014;160:550‚Äì557.318SoFtablesSupplementaryTableS5SearchdateJuly2022
Citationsscreened/includedstudies2184/65
SupplementaryFigureS5Chapter2RiskassessmentinpeoplewithCKDClinicalquestionArekidneyfailurepredictionequationsgoodpredictorsofprogression,kidneyfailure,orend-stagerenaldisease?PopulationAdults,children,andyoungpeoplewithCKDG1-G5PredictorKidneyfailureriskequations(e.g.,Tangriequation[KidneyFailureRiskEquation])OutcomesPrognosticperformance:Calibration(goodnessofmeasures,e.g.,R2,Brierscore,andHosmer-Lemeshowtest)Discrimination(e.g.,sensitivity/specicity;areaunderthecurve[AUC]fromreceiveroperatingcharacteristic[ROC]andareaunderthereceiveroperatingcharacteristiccurve[AUROC];C-statistic)StudydesignSystematicreview
ExistingsystematicreviewNationalInstituteforHealthandCareExcellence.Evidencereviewforthebestcombinationofmeasurestoidentifyincreasedriskofprogressioninadults,childr

---

### Chunk 24/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.468

treatmentforpreventionofmajorcardiovasculardiseasesinpeoplewithandwithouttype2diabetes:anindividualparticipant-leveldatameta-analysis.LancetDiabetesEndocrinol.2022;10:645‚Äì654.500.CheungAK,WheltonPK,MuntnerP,etal.InternationalConsensusonStandardizedClinicBloodPressureMeasurement‚Äîacalltoaction.AmJMed.2023;136:438‚Äì445.501.McManusRJ,MantJ,FranssenM,etal.Efcacyofself-monitoredbloodpressure,withorwithouttelemonitoring,fortitrationof
antihypertensivemedication(TASMINH4):anunmaskedrandomisedcontrolledtrial.Lancet.2018;391:949‚Äì959.502.JanseRJ,FuEL,ClaseCM,etal.Stoppingversuscontinuingrenin-angiotensin-systeminhibitorsafteracutekidneyinjuryandadverseclinicaloutcomes:anobservationalstudyfromroutinecaredata.ClinKidneyJ.2022;15:1109‚Äì1119.503.LeonSJ,WhitlockR,RigattoC,etal.Hyperkalemia-related
discontinuationofrenin-angiotensin-aldosteronesysteminhibitorsand
clinicaloutcomesinCKD:apopulation-basedcohortstudy.AmJKidneyDis.2022;80:164‚Äì173.504.SiewED,ParrSK,Abdel-KaderK,etal.Renin-angiote

---

### Chunk 25/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** other | **Similarity:** 0.467

Rcategory(ml/minper1.73m2)105D90‚Äì10475‚Äì8960‚Äì7445‚Äì5930‚Äì4415‚Äì290‚Äì14Serumpotassium$65Female4.1(0.5)4.2(1.3)4.2(0.5)4.3(0.5)4.3(1.3)4.4(0.5)4.5(1.0)4.5(2.0)Male4.2(0.5)4.3(0.6)4.3(1.1)4.4(0.6)4.4(0.7)4.5(1.1)4.6(0.6)4.6(1.6)<65Female4.1(0.7)4.2(1.3)4.3(17.0)4.2(1.0)4.3(0.5)4.3(0.6)4.4(0.6)4.5(1.1)Male4.2(0.4)4.3(0.5)4.3(0.6)4.3(0.4)4.4(0.5)4.5(0.6)4.5(0.7)4.6(0.7)eGFR,estimatedglomerularltrationrate;GFR,glomerularltrationrate.aDatafromtheOptumLabsDataWarehouse,alongitudinal,real-worlddataassetwithdeidentiedadministrativeclaimsandelectronichealthrecorddata.Thedatabasecontainslongitudinalhealthinformationonenrolleesandpatients,representingthediversityofgeographicalregionsacrosstheUnitedStates.

---

### Chunk 26/30
**Article:** Multiparametric Ultrasound for Focal Testicular Pathology: A Ten-Year Retrospective Review (2024)
**Journal:** Cancers (Basel)
**Section:** other | **Similarity:** 0.466

-enhancedultrasound(CEUS)andreal-timetissueelastography(RTE).J.Ultrasound2014,17,233‚Äì238.[CrossRef]30.Zebari,S.;Huang,D.Y.;Wilkins,C.J.;Sidhu,P.S.AcuteTesticularSegmentalInfarctFollowingEndovascularRepairofaJuxta-renalAbdominalAorticAneurysm:CaseReportandLiteratureReview.Urology2019,126,5‚Äì9.[CrossRef]

Cancers2024,16,2309
16of17
31.Kachramanoglou,C.;Rafailidis,V.;Philippidou,M.;Bertolotto,M.;Huang,D.Y.;Deganello,A.;Sellars,M.E.;Sidhu,P.S.MultiparametricSonographyofHematologicMalignanciesoftheTestis:Grayscale,ColorDoppler,andContrast-EnhancedUltrasoundandStrainElastographicAppearancesWithHistologicCorrelation.J.UltrasoundMed.2016,36,409‚Äì420.[CrossRef][PubMed]32.Huang,D.Y.;Sidhu,P.S.Focaltesticularlesions:ColourDopplerultrasound,contrast-enhancedultrasoundandtissueelastogra-phyasadjuvantstothediagnosis.Br.J.Radiol.2012,85,S41‚ÄìS53.[CrossRef][PubMed]33.Huang,D.Y.;Pesapane,F.;Rafailidis,V.;Deganello,A.;Sellars,M.E.;Sidhu,P.S.Theroleofmultiparametricultrasoundinthediagnosisofpaediatr

---

### Chunk 27/30
**Article:** Hipertens√£o Arterial Sist√™mica (2024)
**Journal:** Pos Graduacao MFI
**Section:** other | **Similarity:** 0.466

egros).
    *   Excesso de peso, obesidade, sedentarismo, tabagismo.
    *   Ingest√£o de s√≥dio e √°lcool.
    *   Fatores gen√©ticos e socioecon√¥micos.
*   **Causas Prim√°rias vs. Secund√°rias:**
    *   95% dos casos s√£o classificados como hipertens√£o prim√°ria (essencial), atribu√≠da √† gen√©tica e estilo de vida.
    *   O palestrante argumenta que causas secund√°rias s√£o subdiagnosticadas, como apneia obstrutiva do sono (presente em 40% dos hipertensos), disfun√ß√µes tireoidianas e doen√ßa renal cr√¥nica. O tratamento da causa base pode curar a hipertens√£o.
### 2. Fisiopatologia e Diagn√≥stico
*   **Fisiopatologia Complexa:**
    *   A press√£o arterial (PA = D√©bito Card√≠aco x Resist√™ncia Vascular Perif√©rica) √© regulada por m√∫ltiplos sistemas: neural (catecolaminas), hormonal (sistema renina-angiotensina-aldosterona - SRAA), renal, microbiota e endot√©lio.

---

### Chunk 28/30
**Article:** hs-CRP/HDL-C can predict the risk of all-cause mortality in cardiovascular-kidney-metabolic syndrome stage 1-4 patients (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.466

,HuY,WangW,etal.Thepredictivevalueofthehs-CRP/HDL-Cratio,aninammation-lipidcompositemarker,forcardiovasculardiseaseinmiddle-agedandelderlypeople:evidencefromalargenationalcohortstudy.
LipidsHealthDis.(2024)23:66.doi:10.1186/s12944-024-02055-729.ZhaoY,HuY,SmithJP,StraussJ,YangG.Cohortprole:theChinahealthandretirementlongitudinalstudy(CHARLS).IntJEpidemiol.(2012)43:61‚Äì8.doi:10.1093/ije/dys20330.D‚ÄôAgostinoRB,VasanRS,PencinaMJ,WolfPA,CobainM,MassaroJM,etal.Generalcardiovascularriskproleforuseinprimarycare.Circulation(2008)117:743‚Äì53.doi:10.1161/CIRCULATIONAHA.107.69957931.MaY-C,ZuoL,ChenJ-H,LuoQ,YuX-Q,LiY,etal.Modiedglomerularltrationrateestimatingequationforchinesepatientswithchronickidneydisease.JAmSocNephrol(2006)17:2937‚Äì44.doi:10.1681/asn.200604036832.JamesPA,OparilS,CarterBL,CushmanWC,Dennison-HimmelfarbC,HandlerJ,etal.Evidence-Basedguidelineforthemanagementofhighbloodpressureinadults:
reportfromthepanelmembersappointedtotheeighthjointnationalcommittee(JNC8).

---

### Chunk 29/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** results | **Similarity:** 0.465

k forrecurrence afterkidney transplantationConditions for whichgenetic testing isrelevant for reproductivecounselingExamples:‚Ä¢ GLA (Fabry)‚Ä¢ AGXT (primaryhyperoxaluria (PH))‚Ä¢ CoQ10 genes (SRNS)‚Ä¢ CTNS (cystinosis)‚Ä¢ Tubulopathies(Na+, K+ etc.)Conditions amenable to nonspecific renoprotective strategiesExample:‚Ä¢ COL4A3/4/5 (Alport)and RAAS blockadeExample:
‚Ä¢ Glomerular diseasedue to mutations inAlport genes(COL4A3/4/5)Examples:‚Ä¢ (CFH/CFI/C3...): aHUS‚Ä¢ (AGXT, GRHPR, HOGA): primary hyperoxaluria (PH)
‚Ä¢ Adenine phosphoribo-  syltransferase deficiency (APRT)Conditions amenable to specific screening for extrarenal manifestationsExamples:‚Ä¢ HNF1B: diabetes‚Ä¢ PKD1/PKD2(ADPKD): intracranialaneurysms ‚Ä¢ FLCN: renal cellcarcinoma, etc.Example:
‚Ä¢ Prenatal/preimplantationdiagnosis
Figure9|Actionablegenesinkidneydisease.Actionabilityreferstothepotentialforgeneticrestresultstoleadtospecicclinicalactionsfrompreventionortreatmentofacondition,supportedbyrecommendationsbasedonevide

---

### Chunk 30/30
**Article:** KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024)
**Journal:** Kidney International
**Section:** discussion | **Similarity:** 0.460

netheprognosticvalueofcirculatingcardiacbiomarkersinadvancedchronickidneydisease.CanJCardiol.2019;35:1106‚Äì1113.663.ColletJP,ThieleH,BarbatoE,etal.2020ESCGuidelinesforthe
managementofacutecoronarysyndromesinpatientspresentingwithoutpersistentST-segmentelevation.EurHeartJ.2021;42:1289‚Äì1367.664.KonoK,FujiiH,NakaiK,etal.Compositionandplaquepatternsof
coronaryculpritlesionsandclinicalcharacteristicsofpatientswith
chronickidneydisease.KidneyInt.2012;82:344‚Äì351.665.SchiffrinEL,LipmanML,MannJF.Chronickidneydisease:effectsonthecardiovascularsystem.Circulation.2007;116:85‚Äì97.666.NationalInstituteforHealthandCareExcellence.Familialhypercholesterolaemia:identicationandmanagement.ClinicalGuideline[CG71].NICE.2008.667.CollinsR,ReithC,EmbersonJ,etal.Interpretationoftheevidencefortheefcacyandsafetyofstatintherapy.Lancet.2016;388:2532‚Äì2561.668.CholesterolTreatmentTrialistsCollaboration.Effectofstatintherapyon
musclesymptoms:anindividualparticipantdatameta-analysisoflarge-
scale,randomised,d

---

